Liisa Hurme, who has a background in research and has held various executive positions at Orion for a long time, has started as President and CEO. Hurme says that there are currently many projects underway related to growth and strengthening sustainability.
Orion extends our deepest sympathy with those living through the earthquake crisis in Turkey and Syria. We have also continued to support Ukraine in the country’s fight against Russian invasion.
Orion condemns Russia’s invasion of Ukraine. The concern for our employees in Ukraine is great and our thoughts are with them at the moment, as well as with all those affected by the war.
Orion is modernising production at its Turku plant through an investment of EUR 17 million.
Appropriate medication is an essential part of patient safety. Drug safety refers to both the product itself and the way that it is administered. The responsibility lies with the entire treatment chain, starting with the manufacturer and ending, to some degree, with patients themselves.
New digital tools benefit both patients and health care professionals, helping improve the treatment of Parkinson's disease, for example. They may also help ease the challenges of rising health care costs for public spending.
A new research ecosystem has been set up in Finland in which the country’s leading research organisations, together with the Finnish Red Cross Blood Service, Orion Pharma and nanotechnology SMEs, are joining forces to develop new types of nanobiotechnological solutions for the treatment and early diagnostics of severe progressive diseases.
Orion implements responsible medication and states in its value proposition that it wants to be a medicine cabinet for Finns. Based on this, Orion is the sole manufacturer or distributor of many pharmaceuticals in Finland.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
Thanks to biosimilars, an increasing number of patients can receive effective care at a lower pharmaceutical cost.